Key Insights

Highlights

Success Rate

66% trial completion

Published Results

14 trials with published results (40%)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

31.4%

11 terminated out of 35 trials

Success Rate

65.6%

-20.9% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

67%

14 of 21 completed with results

Key Signals

14 with results66% success11 terminated

Data Visualizations

Phase Distribution

35Total
Not Applicable (4)
Early P 1 (2)
P 1 (24)
P 2 (5)

Trial Status

Completed21
Terminated11
Withdrawn2
Active Not Recruiting1

Trial Success Rate

65.6%

Benchmark: 86.5%

Based on 21 completed trials

Clinical Trials (35)

Showing 20 of 20 trials
NCT00268385Phase 1Active Not RecruitingPrimary

Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas

NCT01165632Early Phase 1CompletedPrimary

Fluorine F 18 Fluorodopa-Labeled PET Scan in Planning Surgery and Radiation Therapy in Treating Patients With Newly Diagnosed High- or Low-Grade Malignant Glioma

NCT02186509Phase 1CompletedPrimary

Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas

NCT02015819Phase 1CompletedPrimary

Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas

NCT01051557Phase 1CompletedPrimary

Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma

NCT01478321Phase 2TerminatedPrimary

Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas

NCT01103375Phase 1TerminatedPrimary

Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant Glioma

NCT01234805Not ApplicableTerminatedPrimary

Yoga Therapy in Treating Patients With Malignant Brain Tumors

NCT01644955Phase 1CompletedPrimary

Carboplatin in Treating Patients With Recurrent High-Grade Gliomas

NCT01648348Phase 1CompletedPrimary

Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme

NCT01234740Phase 1CompletedPrimary

Bafetinib in Treating Patients With Recurrent High-Grade Glioma or Brain Metastases

NCT01172964Phase 1CompletedPrimary

A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade Gliomas

NCT00045708Phase 1CompletedPrimary

A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade Gliomas

NCT00045110Phase 1CompletedPrimary

Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma

NCT00823797Phase 2CompletedPrimary

Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma

NCT02194452Not ApplicableWithdrawn

Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors

NCT01996527Early Phase 1TerminatedPrimary

3T MRI Biomarkers of Glioma Treatment Response

NCT02967380Not ApplicableTerminated

Gadobutrol Versus Gadopentetate Dimeglumine or Gadobenate Dimeglumine Before DCE-MRI in Diagnosing Patients With Multiple Sclerosis, Grade II-IV Glioma, or Brain Metastases

NCT01148966Phase 1TerminatedPrimary

Aminolevulinic Acid During Surgery in Treating Patients With Malignant Brain Tumors

NCT00085540Phase 1CompletedPrimary

FR901228 in Treating Patients With Recurrent High-Grade Gliomas

Scroll to load more

Research Network

Activity Timeline